Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population (Q36444054)

14 August 2017

Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population (English)

1 reference

14 August 2017

1 reference

Anne L Peters

5

0 references

Daniel McFadden

series ordinal

4

object named as

Daniel McFadden

1 reference

14 August 2017

John A Romley

1

1 reference

14 August 2017

Dana P Goldman

series ordinal

2

1 reference

14 August 2017

Matthew Solomon

series ordinal

3

1 reference

14 August 2017

30 July 2012

1 reference

Diabetes technology & therapeutics

14 August 2017

1 reference

14 August 2017

14

1 reference

14 August 2017

10

1 reference

14 August 2017

904-911

1 reference

The safety of incretin-based therapies--review of the scientific evidence

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

A cohort study of acute pancreatitis in relation to exenatide use.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Exenatide-induced acute pancreatitis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Cost sharing and the initiation of drug therapy for the chronically ill.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Predictive margins with survey data

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Pharmacy benefits and the use of drugs by the chronically ill.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Employer drug benefit plans and spending on prescription drugs

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Exenatide (exendin-4)-induced pancreatitis: a case report.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3513976

Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22845701

12 December 2020

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/22845701

12 December 2020

inferred from PubMed ID database lookup

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22845701

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1089/DIA.2012.0075

1 reference

release_wrdaemwzyzhmjlwyibs5vnhvji

14 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wrdaemwzyzhmjlwyibs5vnhvji

24 November 2022

mapped directly with Wikidata item

1 reference

14 August 2017

PubMed publication ID

22845701

1 reference